Skip to main content
. 2022 May 18;26:143. doi: 10.1186/s13054-022-03997-z

Table 2.

Demographic, nutrition, clinical, and follow-up characteristics of the study population

Characteristic (n = 1172a) No. (%) or median [Q1;Q3]
Age, years 66.0 [56.0;74.0]
Sex
 Male 745 (63.6)
 Female 427 (36.4)
BMI, kg/m2, n = 1168 26.8 [24.0;31.1]
APACHE II score at ICU admission, n = 1132 18.5 [13.0;26.0]
SOFA score at ICU admission, n = 1042 7.0 [4.0;10.0]
Number of comorbidities at ICU admission 3.0 [1.0;5.0]
Type of ICU admission
 Non-surgical emergency 573 (48.9)
 Surgical emergency 360 (30.7)
 Surgical elective 220 (18.8)
 Others 19 (1.6)
Main reason(s) for ICU admissionb
 Respiratory 546 (46.6)
 Infection 362 (30.9)
 Cardiac 343 (29.3)
 Hepatic/GI/digestive 279 (23.8)
 Neurological 134 (11.4)
 Renal 126 (10.8)
 Trauma 116 (9.9)
 Others 74 (6.3)
Sedationc 885 (75.5)
Sum of days on sedation, n = 885 5.0 [2.0;10.0]
Vasopressorsc 886 (75.6)
Sum of days on vasopressors, n = 886 4.0 [2.0;8.0]
Ventilatory supportc,d 988 (84.3)
Sum of days on ventilatory support, n = 988 7.0 [4.0;13.0]
Invasive mechanical ventilation between day 1 to 3 of ICU admission 813 (69.4)
Physiotherapyc 1006 (85.8)
Sum of days on physiotherapy, n = 1006 7.0 [4.0;11.0]
Healthcare-associated infections after day 3 of ICU admission 230 (19.6)
Days in ICU until first infection, n = 230 6.0 [4.0;9.0]
Mobility status (IMS score) 10.0 [8.0;10.0]
 before ICU admission, n = 1168 10.0 [8.0;10.0]
 At day 15, n = 1057 5.0 [1.0;10.0]
 At day 30, n = 949 9.0 [3.0;10.0]
 At day 90, n = 844 10.0 [9.0;10.0]
ICU LOS, days, n = 1158 10.0 [7.0;16.0]
Hospital LOS, days, n = 1077 23.0 [15.0;36.0]
ICU mortality, n = 1082 168 (15.5)
Hospital mortality, n = 1082 244 (22.6)
90-day mortality, n = 1172 276 (23.5)

APACHE acute physiology and chronic health evaluation, BMI body mass index, ICU intensive care unit, IMS ICU mobility scale, IQR interquartile range, LOS length of stay, SOFA Sequential Organ Failure Assessment

aUnless otherwise indicated

bMultiresponse variable

cOn at least one day during the first 15 observation days

dIncludes invasive, noninvasive ventilation and high flow nasal oxygen therapy